Sunday, February 17, 2013
Room 306 (Hynes Convention Center)
Dealing with DNA at the nanoscale was a technical challenge whose solution ultimately enabled next-generation sequencing (NGS). By integrating advances in chemistry, biology, and engineering, sequencing throughput has increased to the point where the true potential of the human genome is being directly brought to the clinic. Illumina and other companies are actively exploiting the application of NGS to healthcare, a tangible benefit of advanced DNA nanotechnology.